Navigation Links
New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
Date:9/25/2008

ffects of treatment may be most appreciable in women over age 50.

The third abstract used the same patient population to investigate the effect of body mass index (less than or equal to 30, > 30) and BMI plus Divigel(R) (1.0 g/day, 0.5 g/day, 0.25 g/day) combined compared to placebo on the change from baseline to week 12 in the frequency and severity of hot flashes. Results indicated that body mass index had a significant interaction with treatment on both the frequency (P =0.036) and severity (P =0.019) of hot flashes, whereas, normal/overweight women experienced a significant reduction in both the frequency and severity of hot flashes (P <0.0001).

"Estrogen therapies, such as Divigel(R), continue to be the gold standard for the management of hot flashes and transdermal therapies, in particular, are emerging as safe and effective alternatives for women experiencing the most common physical sign of menopause," said Dr. Ackerman.

The estrogen in Divigel(R) is derived from plant sources and is identical to the primary estrogen produced by a woman's ovaries before menopause. Divigel(R) is a quick-drying gel that is odorless when dry, and is available in convenient, individual-use packets. One packet of gel is applied daily to an area that measures approximately 5 x 7 inches on the thigh, the smallest application area compared to all other available gel or lotion estrogen products. Divigel(R) also offers dosing flexibility with three different strengths (0.25 mg estradiol/day, 0.5 mg estradiol/day and 1.0 mg estradiol/day) to individualize treatment for each woman.

For more information, call 1-800-654-2299 or visit http://www.divigelus.com.

Important Safety Information

Estrogens should not be used in women with undiagnosed abnormal vaginal bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or history of deep vein th
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , NEW YORK, Nov. 20 /PRNewswire-FirstCal...s today contributing to a transformation in Americ...paradigm that is already delivering higher quality...curve downward -- making medicine smarter for the ...mpany today explained how the elements in its stra...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 ...t research report is available in its catalogue. ,...Forecasts to 2015 ,, http://www.reportlinker...sis-and-Forecasts-to-2015.html#utm_source=prnewswi... ,, Description ,, India Medical Equipment...
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCa...unced results for its first quarter ended Septembe... per diluted share, on revenues of $3,263,000. Th...per diluted share, on revenues of $3,168,000 for t... the first quarter results, Biotel President and C...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Biotel Announced Profitable First Quarter Ended September 30, 2009 2Early initiation of Arctic sea ice formation 9271 1Early initiation of Arctic sea ice formation 9271 2Early initiation of Arctic sea ice formation 9271 3Pulmonx Announces New President and CEO Michael A Baker to Lead Interventional Pulmonology Company 51853 1Pulmonx Announces New President and CEO Michael A Baker to Lead Interventional Pulmonology Company 51853 2Pulmonx Announces New President and CEO Michael A Baker to Lead Interventional Pulmonology Company 51853 3Grubb 26 Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 51851 1Grubb 26 Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 51851 2Grubb 26 Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 51851 3
... Company extension to address remaining questions ...pplication, IRVINE, Calif., Jan. 25 IDM Pharma, ...pany recently presented to the,Committee for Medic...,committee of the European Medicines Evaluation Ag... Application (MAA) for mifamurtide (L-MTP-PE) for,...
...Va., Jan. 25 A report released,today by The Cornu...new,additives placed in infant formula are serious...orns and toddlers., The report, ,Replacing Mother...etails research questioning the alleged benefits o...laboratories and extracted from,algae and fungus, ...
Other Medicine Technology:IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 2IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 3IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 4IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 5Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 2Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 3
(Date:11/20/2009)...o Understanding Brain Wiring and Diseases ,, WA...eremy Schmahmann, Professor of Neurology at Harvar...tts General Hospital in Boston, on Thursday, Novem... new field of study called "Connectivity" at the l...mann is an award-winning leader in the field of th...
(Date:11/20/2009)...gressmen in Competitive Re-election Battles Could ... Washington, DC (Vocus) November...re-election next year in races deemed to be compet...regret voting for House Speaker Nancy Pelosi&rsquo... International/ O’Leary Report poll. (The ...
(Date:11/20/2009)...RNewswire-USNewswire/ -- Samuel Gladding is no Scr...eans to be "happy" during the holidays. As a licen...ily counseling and chair of the Department of Coun...search shows that it is the pressure to be happy t...ing the holidays. ,, That,s why he,s challengin...
(Date:11/20/2009)... with chronic kidney disease often fail to detect ...increasing a child,s risk for serious heart proble...ren,s Center and other institutions. A report of t...can Society of Nephrology. , Researchers compa...gular doctor visits to readings obtained via a spe...
(Date:11/20/2009)...n with seasonal flu , , FRIDAY, Nov. 20...rting that children with asthma are more likely to...u. , "Asthma has been identified as a significa...fluenza, present in 21 percent to 30 percent in th...w researchers from the Hospital for Sick Children ...
Breaking Medicine News(10 mins):Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Just 25% of Voters in Competitive 2010 Senate Races &#8220;Much More Likely&#8221; to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races &#8220;Much More Likely&#8221; to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:High blood pressure easy to miss in children with kidney disease 2
...re Platform-HealthRules(R)-Poised to ...GTON, Mass., April 22 HealthEdge, the leading,pro...stration, business,intelligence and portal softwar...ure capital and private equity firm., "We believe...
..., Will Earn a 16 Percent Patient Share in the Bip...eport from Decision Reso...es, one of the,world,s leading research and adviso...nd has both antimanic and antidepressant,effects w...
...gency Services, a,division of Omnicom Group Inc. (...lthcare and pharmaceutical agencies Cline Davis Ma...of the Year Awards at the 19th Annual,Manny Awards...mpetition in Category II (agencies with $10 millio...
...ida,Pharmaceuticals, Inc. (OTC Bulletin Board: AID...-focused corporate synopsis on its English,languag...e downloaded as a,pdf document. The synopsis detai...re growth avenues., About Aida Pharmaceuticals, ...
...3-Minute,Press Show is a daily video program hoste...ws air Monday through Friday on:, http://tv.wallst...-Minute Press Show features in-depth interviews wi...st,recent press release, and its impact on the com...
...ollege of Allergy,Asthma & Immunology (ACAAI) rece... surveys that highlight the importance of improvin...survey findings and other important,information fo...g the dialogue about unmet needs for patients with...
Other Medicine News:Health News:HealthEdge Receives $13 Million Investment Commitment to Fund Significant Growth 2Health News:A Drug That Carries a Lower Risk of Weight Gain Than AstraZeneca's Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment 2Health News:Omnicom's Diversified Agency Services Healthcare Agencies Top Med Ad News' Manny Awards 2Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: CYRX, RHWI 2
Automatic Tangent Screen
Focus Toric Monthly lenses
...Made Toric soft contact lenses let you enjoy a lev...ns in a lens custom made to fit your eye., Th...y PC Technology™, which creates a unique mat...C), a substance found naturally in human cell memb...
Hydrasoft® Toric
Medicine Products: